The firm is preparing to test a gene replacement therapy that uses an ultrasound-mediated strategy to deliver a full-length ...

The agency expects to issue decisions on Vyondys 53 and Amondys 45, which missed their primary endpoint in a confirmatory trial, by February 2027.

Innovent Biologics will commercialize Eli Lilly's CDK4/6 inhibitor Verzenio (abemaciclib) in mainland China, where it is called Verzenios, the companies announced Tuesday. Lilly will retain rights to ...

The acquisition will bring navtemadlin, Kartos' late-stage treatment program in myelofibrosis, to Ipsen's pipeline.

The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...

During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...

The European Commission on Monday approved AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as a tissue-agnostic treatment for previously treated patients with unresectable or ...

The firm also said it completed enrollment in the Phase III 4FRONT-2 clinical trial of 4D-150 in wet AMD ahead of schedule.

The company is planning to test its oral immunotherapy in over 800 patients with resectable and unresectable tumors.

The program will help make genetic counselors available to any provider across different medical specialties in Tennessee and ...

Three cases suggest some clinicians lack understanding of relatively common autosomal recessive disorders and are ...

The positive decision is based on results from a Phase III study evaluating first-line Datroway against chemotherapy.